HEALTHCARE
Untitled Page
Hoag becomes first OC hospital to provide effective chronic reflux treatment
The LINX treatment shows successful results in stopping acid reflux
by Samar KhouryPublished: December 21, 2012 10:15 AM
Hoag Memorial Hospital Presbyterian in Newport Beach recently became one of three medical centers in California – and the only hospital in Orange County – to offer a new treatment for chronic reflux disease (or acid reflux), a condition that affects 15 percent of Americans.
The treatment, known as the LINX Reflux Management System, stopped chronic reflux in 75 to 80 percent of all patients who participated in two national trials, leading the Federal Drug Administration FDA to approve the treatment this year. Hoag performed its first procedure in October.
“For millions of Americans who suffer from chronic reflux disease, one of life’s normally most pleasurable experiences – enjoying a meal – can instead become a daily chore they anticipate with dread,” said Dr. John Lipham, director of the Foregut Cancer Program and chief of USC Affiliated Academic Programs at Hoag. “In addition, chronic reflux can cause severe discomfort, robbing people of their sleep. Even in the limited time since its approval by the FDA, the LINX Reflux Management System has literally transformed the lives of our patients with chronic reflux disease.”
Dr. Lipham was the principal investigator at USC for the FDA-regulated trial of the LINX treatment and performs the procedure at Hoag with Dr. Nikolai Bildzukewicz.
During the LINX procedure, doctors place a device in the lower esophagus that prevents the backward flow of stomach contents that leads to acid reflux.
The procedure has been successful so far, as Dr. Lipham recently treated a woman who no longer suffers from a severe case of chronic reflux.
Related headlines
Hoag launches new affordable care joint initiative
Hoag unveils new model for cardiac care
Hoag hospital first in state to offer 3D mammogram
|
||||
|
The treatment, known as the LINX Reflux Management System, stopped chronic reflux in 75 to 80 percent of all patients who participated in two national trials, leading the Federal Drug Administration FDA to approve the treatment this year. Hoag performed its first procedure in October. “For millions of Americans who suffer from chronic reflux disease, one of life’s normally most pleasurable experiences – enjoying a meal – can instead become a daily chore they anticipate with dread,” said Dr. John Lipham, director of the Foregut Cancer Program and chief of USC Affiliated Academic Programs at Hoag. “In addition, chronic reflux can cause severe discomfort, robbing people of their sleep. Even in the limited time since its approval by the FDA, the LINX Reflux Management System has literally transformed the lives of our patients with chronic reflux disease.” Dr. Lipham was the principal investigator at USC for the FDA-regulated trial of the LINX treatment and performs the procedure at Hoag with Dr. Nikolai Bildzukewicz. During the LINX procedure, doctors place a device in the lower esophagus that prevents the backward flow of stomach contents that leads to acid reflux. The procedure has been successful so far, as Dr. Lipham recently treated a woman who no longer suffers from a severe case of chronic reflux. Related headlines Hoag launches new affordable care joint initiative Hoag unveils new model for cardiac care Hoag hospital first in state to offer 3D mammogram |
||||
